Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB) and Ethypharm have been selected as exclusive suppliers for the French medical marijuana trial, which has been extended until March 2024. This partnership and the extension of the trial period will likely have a positive impact on Aurora Cannabis' stock price in the short term, as it demonstrates the company's continued success in securing contracts and expanding its presence in the European medical cannabis market.